Leda P Mannent
Leda P Mannent is an expert in Allergy at Sanofi (France) (France). As of July 2026, ScienceLeadR ranks Leda P Mannent in the top 1% of experts worldwide for Nose Diseases and Hypersensitivity, and in the top 1% of experts in France for Rhinosinusitis. Leda P Mannent has authored 137 publications, the most recent in 2026, and is an investigator in 12 clinical trials. SLR score: 679 (community average: 125). How the SLR is computed.
LeadR Profile
Allergy
Subspecialties: Immunology - Pulmonology - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2016 - 2026
Number : 137
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| A phase 2 trial of rilzabrutinib in IgG4-related disease. PMID 42481271 — safety, immunoglobulin g4-related disease, rheumatic diseases, rituximab, therapeutics | Ann Rheum Dis | 2026 | 0 |
| Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma. PMID 42215290 — cells, genes, lung, safety, blood, hypersensitivity, eosinophils, bronchoscopy, biopsy, biomarkers, cell count, asthma, gene expression | Allergy | 2026 | 0 |
| Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study. PMID 41936356 — pharmaceutical preparations, signs and symptoms, therapeutics, asthma | Lancet Respir Med Top journal | 2026 | 0 |
| Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial. PMID 40317187 — syphilis, safety, dermatitis, therapeutics, dermatology, dermatitis, atopic | Br J Dermatol | 2025 | 0 |
| Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial. PMID 40266575 — cells, omalizumab, histamine antagonists, urticaria, skin diseases, drug-related side effects and adverse reactions, mast cells | JAMA Dermatol | 2025 | 13 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
LeadR Networks
Main global connection map